Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Michael Lewiecki

Showing results (21-30 of 253) with videos related to

Pageof 26
Sort By:
Current Osteoporosis Reports|April 21, 2011
The role of risk communication in the care of osteoporosisE Michael Lewiecki
Current Osteoporosis Reports|February 26, 2017
Osteoporosis: Treat-to-TargetE Michael Lewiecki
Current Rheumatology Reports|March 12, 2005
Premenopausal bone health assessmentE Michael Lewiecki
Current Osteoporosis Reports|September 1, 2005
Review of guidelines for bone mineral density testing and treatment of osteoporosisE Michael Lewiecki
Expert Opinion on Biological Therapy|December 21, 2012
Monoclonal antibodies for the treatment of osteoporosisE Michael Lewiecki
Idrugs : the Investigational Drugs Journal|November 28, 2009
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodelingE Michael Lewiecki
Therapeutics and Clinical Risk Management|November 10, 2009
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosisE Michael Lewiecki
Therapeutic Advances in Musculoskeletal Disease|November 3, 2018
New and emerging concepts in the use of denosumab for the treatment of osteoporosisE Michael Lewiecki
Expert Opinion on Investigational Drugs|October 10, 2007
Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosisE Michael Lewiecki
Expert Opinion on Biological Therapy|January 26, 2010
Denosumab--an emerging treatment for postmenopausal osteoporosisE Michael Lewiecki
Pageof 26

Showing results (21-30 of 253) with videos related to

Sort By:
Pageof 26
Current Osteoporosis Reports|April 21, 2011
The role of risk communication in the care of osteoporosisE Michael Lewiecki
Current Osteoporosis Reports|February 26, 2017
Osteoporosis: Treat-to-TargetE Michael Lewiecki
Current Rheumatology Reports|March 12, 2005
Premenopausal bone health assessmentE Michael Lewiecki
Current Osteoporosis Reports|September 1, 2005
Review of guidelines for bone mineral density testing and treatment of osteoporosisE Michael Lewiecki
Expert Opinion on Biological Therapy|December 21, 2012
Monoclonal antibodies for the treatment of osteoporosisE Michael Lewiecki
Idrugs : the Investigational Drugs Journal|November 28, 2009
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodelingE Michael Lewiecki
Therapeutics and Clinical Risk Management|November 10, 2009
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosisE Michael Lewiecki
Therapeutic Advances in Musculoskeletal Disease|November 3, 2018
New and emerging concepts in the use of denosumab for the treatment of osteoporosisE Michael Lewiecki
Expert Opinion on Investigational Drugs|October 10, 2007
Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosisE Michael Lewiecki
Expert Opinion on Biological Therapy|January 26, 2010
Denosumab--an emerging treatment for postmenopausal osteoporosisE Michael Lewiecki
Pageof 26